Skip to main content
Erschienen in: Journal of Neurology 8/2014

01.08.2014 | Original Communication

Measuring disease progression in corticobasal syndrome

verfasst von: Nancy Huang, Michael Hornberger, John R. Hodges, James R. Burrell

Erschienen in: Journal of Neurology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Corticobasal syndrome (CBS) is a complex neurodegenerative disorder with marked clinical, neuropsychological, and pathological heterogeneity. Measurement of disease progression in CBS is complex and little understood. This study aimed to establish clinical and neuropsychological indicators of prognosis in CBS. Patients with CBS were retrospectively recruited from a frontotemporal dementia specific research clinic. All patients underwent detailed clinical and neuropsychological testing including the frontotemporal dementia rating scale (FRS). Using the differences in FRS logit scores over a period of 12 months, CBS patients were divided into rapid and slow progressor groups. Demographic, clinical and neuropsychological features were compared between the two groups. Sixteen participants who met defined criteria were included (9 males, 7 females; mean age 65.8 ± 22 years; median symptom duration 51.8 ± 22 years; mean duration of follow-up 11.4 ± 2.8 months). There were no significant differences between the rapid and slow progressors in age, gender, symptom duration, motor/cognitive presentation, and ACE-R scores at baseline. Clinically, slow progressors were significantly more likely to have a motor speech disorder, with a trend for more frequent dysgraphia, whereas rapid progressors were more likely to exhibit surface dyslexia. Rapid and slow progressor groups did not differ on neuropsychological performance. The presence of motor speech disorder, dysgraphia, and surface dyslexia may be useful in differentiating patients with rapid progression of CBS from those with a more indolent disease course.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Boeve BF, Maraganore DM, Parisi JE et al (1999) Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53:795CrossRefPubMed Boeve BF, Maraganore DM, Parisi JE et al (1999) Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53:795CrossRefPubMed
5.
Zurück zum Zitat Kertesz A, Martinez-Lage P, Davidson W, Munoz DG (2000) The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 55:1368–1375CrossRefPubMed Kertesz A, Martinez-Lage P, Davidson W, Munoz DG (2000) The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 55:1368–1375CrossRefPubMed
10.
Zurück zum Zitat Dickson DW, Bergeron C, Chin SS et al (2002) Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946PubMed Dickson DW, Bergeron C, Chin SS et al (2002) Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946PubMed
11.
Zurück zum Zitat Shiozawa M, Fukutani Y, Sasaki K et al (2000) Corticobasal degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. Clin Neuropathol 19:192–199PubMed Shiozawa M, Fukutani Y, Sasaki K et al (2000) Corticobasal degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. Clin Neuropathol 19:192–199PubMed
14.
Zurück zum Zitat Horoupian DS, Chu PL (1994) Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles. Acta Neuropathol 88:592–598CrossRefPubMed Horoupian DS, Chu PL (1994) Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles. Acta Neuropathol 88:592–598CrossRefPubMed
17.
Zurück zum Zitat Hodges JR, Davies R, Xuereb J et al (2003) Survival in frontotemporal dementia. Neurology 61:349–354CrossRefPubMed Hodges JR, Davies R, Xuereb J et al (2003) Survival in frontotemporal dementia. Neurology 61:349–354CrossRefPubMed
18.
Zurück zum Zitat Roberson ED, Hesse JH, Rose KD et al (2005) Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 65:719–725CrossRefPubMed Roberson ED, Hesse JH, Rose KD et al (2005) Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 65:719–725CrossRefPubMed
21.
Zurück zum Zitat Graham NL, Bak T, Patterson K, Hodges JR (2003) Language function and dysfunction in corticobasal degeneration. Neurology 61:493–499CrossRefPubMed Graham NL, Bak T, Patterson K, Hodges JR (2003) Language function and dysfunction in corticobasal degeneration. Neurology 61:493–499CrossRefPubMed
22.
Zurück zum Zitat Takao M, Tsuchiya K, Mimura M et al (2006) Corticobasal degeneration as cause of progressive non-fluent aphasia: clinical, radiological and pathological study of an autopsy case. Neuropathology 26:569–578CrossRefPubMed Takao M, Tsuchiya K, Mimura M et al (2006) Corticobasal degeneration as cause of progressive non-fluent aphasia: clinical, radiological and pathological study of an autopsy case. Neuropathology 26:569–578CrossRefPubMed
30.
Zurück zum Zitat Mioshi E, Dawson K, Mitchell J et al (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21:1078–1085. doi:10.1002/gps.1610 CrossRefPubMed Mioshi E, Dawson K, Mitchell J et al (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21:1078–1085. doi:10.​1002/​gps.​1610 CrossRefPubMed
35.
Zurück zum Zitat Lockhart A, Lamb JR, Osredkar T et al (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130:2607–2615CrossRefPubMed Lockhart A, Lamb JR, Osredkar T et al (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130:2607–2615CrossRefPubMed
40.
Zurück zum Zitat Ioannides P, Karacostas D, Hatzipantazi M, Ioannis M (2005) Primary progressive aphasia as the initial manifestation of corticobasal degeneration. A “three in one” syndrome? Funct Neurol 20:135–137PubMed Ioannides P, Karacostas D, Hatzipantazi M, Ioannis M (2005) Primary progressive aphasia as the initial manifestation of corticobasal degeneration. A “three in one” syndrome? Funct Neurol 20:135–137PubMed
41.
Zurück zum Zitat Mimura M, Oda T, Tsuchiya K et al (2001) Corticobasal degeneration presenting with nonfluent primary progressive aphasia: a clinicopathological study. J Neurol Sci 183:19–26CrossRefPubMed Mimura M, Oda T, Tsuchiya K et al (2001) Corticobasal degeneration presenting with nonfluent primary progressive aphasia: a clinicopathological study. J Neurol Sci 183:19–26CrossRefPubMed
42.
Zurück zum Zitat Fukui T, Lee E (2008) Progressive agraphia can be a harbinger of degenerative dementia. Brain Lang 104:201–210CrossRefPubMed Fukui T, Lee E (2008) Progressive agraphia can be a harbinger of degenerative dementia. Brain Lang 104:201–210CrossRefPubMed
43.
Zurück zum Zitat Grimes DA, Lang AE, Bergeron CB (1999) Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53:1969–1974CrossRefPubMed Grimes DA, Lang AE, Bergeron CB (1999) Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53:1969–1974CrossRefPubMed
44.
Zurück zum Zitat Mathuranath PS, Nestor PJ, Berrios GE et al (2000) A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 55:1613–1620CrossRefPubMed Mathuranath PS, Nestor PJ, Berrios GE et al (2000) A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 55:1613–1620CrossRefPubMed
45.
Zurück zum Zitat Kertesz A, Davidson W, Munoz D (1999) Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Dement Geriatr Cogn Disord 10 Suppl 1:46–49CrossRefPubMed Kertesz A, Davidson W, Munoz D (1999) Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Dement Geriatr Cogn Disord 10 Suppl 1:46–49CrossRefPubMed
46.
Zurück zum Zitat Litvan I, Agid Y, Goetz C et al (1997) Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 48:119–125CrossRefPubMed Litvan I, Agid Y, Goetz C et al (1997) Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 48:119–125CrossRefPubMed
47.
Zurück zum Zitat Schneider JA, Watts RL, Gearing M et al (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48:959–969CrossRefPubMed Schneider JA, Watts RL, Gearing M et al (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48:959–969CrossRefPubMed
Metadaten
Titel
Measuring disease progression in corticobasal syndrome
verfasst von
Nancy Huang
Michael Hornberger
John R. Hodges
James R. Burrell
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 8/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7389-5

Weitere Artikel der Ausgabe 8/2014

Journal of Neurology 8/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.